2020
DOI: 10.1200/jco.2020.38.15_suppl.e17550
|View full text |Cite
|
Sign up to set email alerts
|

Radium 223 treatment in metastatic prostate cancer: Exploring use of clinical factors for prognostication in routine practice.

Abstract: e17550 Background: Skeletal metastases are seen in over 90% of metastatic castrate resistant prostate cancer (mCRPC) patients during the course of their disease and is a major cause for significant morbidity and mortality in them. Radium 223 (Ra-223) is a bone seeking calcium mimetic alpha emitter that has demonstrated significant improvement in survival and reduction in skeletal related events (ALSYMPCA trial). Ra-223 treatment was well tolerated and showed benefit before or after chemotherapy. In this study… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles